Your session is about to expire
← Back to Search
Durvalumab + Radiotherapy for Stage III Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new cancer treatment involving both radiation and a new drug, Durvalumab. The goal is to see if this treatment is effective for Stage III Non-Small Cell Lung Cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My N2 disease was confirmed by a biopsy or a PET/CT scan.My cancer is at a stage where surgery isn't an option due to large lymph nodes in my chest.You have a serious health problem, a history of certain medical conditions, a recent surgery, or are not using contraception during the study.I had lung infection due to blockage but don't need IV antibiotics anymore.I am 18 years old or older.Women who could become pregnant must have a negative pregnancy test within three days before joining the study.I've had radiation in the same area as my current cancer.My lung cancer can be surgically removed, as decided by my surgeon.My cancer has spread to other parts of my body.I have received specific treatments for non-small cell lung cancer.My lung cancer is at stage IIIA or IIIB and cannot be removed with surgery.I haven't taken steroids or immunosuppressants in the last 7 days.I have had limited previous treatments.My cancer stage fits the study requirements based on recent scans and exams.My pleural effusion is non-cancerous and can be treated with radiotherapy.My organs and bone marrow are working well.I have cancer, but it's not skin, localized bladder, prostate cancer, or certain in situ cancers.You are expected to live for at least 12 more weeks.I can carry out all my normal activities without help.My breathing function is normal.
- Group 1: Single Arm: Therapeutic Intervention
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment open for this investigation?
"According to clinicaltrials.gov, this particular medical study is not actively recruiting patients right now. The trial was initially posted on April 3rd 2020 and the last update came through August 16th 2022. However, there are over two thousand three hundred other trials that may be of interest for individuals looking to participate in a medical trial at present."
What conditions are typically treated with Thoracic RT and Durvalumab?
"Thoracic RT and Durvalumab is a treatment regimen applied to unresectable stage 3 non-small cell lung cancer. Additionally, it can be used on patients with metastatic ureter urothelial carcinoma or in advance directives."
To what degree is Thoracic RT and Durvalumab hazardous to the health of participants?
"As is befitting a Phase 2 trial, Thoracic RT and Durvalumab were assessed to have safety levels of 2 on our scale. There is evidence that backs up their security but no data confirming efficacy."
How many participants have signed up for the research study?
"Unfortunately, no additional participants are being sought for this trial which was first opened on April 3rd 2020 and last updated August 16th 2022. On the other hand, there are presently 2045 trials recruiting patients with malignant neoplasms and 333 clinical studies looking for volunteers to receive Thoracic Radiation Therapy in combination with Durvalumab medication."
What prior research has been done involving Thoracic RT and Durvalumab?
"Currently, 333 active clinical trials researching Thoracic RT and Durvalumab are occurring worldwide. Of these investigations, 52 have reached the pivotal Phase 3 stage of testing. Although a large portion of research is based in Cordoba, Texas; an expansive network of medical sites across 12949 locations offer this therapy to participants."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Average response time
- < 2 Days
Most responsive sites:
- Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas: < 48 hours
Share this study with friends
Copy Link
Messenger